News

Gilles Salles, MD, discusses the need for new therapies to treat diffuse large B-cell lymphoma.

In an interview with Targeted Oncology™, Robert Coleman, MD, discussed the evolving treatment paradigm of lung cancer and the role of molecular testing now and in the future. 

Preliminary results from the phase 1b KISIMA-01 indicate that combining the single chimeric fusion protein ATP128 with the PD-1 inhibitor, ezabenlimab, is tolerable in patients with heavily pretreated refractory stage IV colorectal cancer and may induce immune responses.

Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer. 

A correlation between small cell or neuroendocrine carcinoma of the prostate and poor survival outcomes was revealed, despite treatment with the combination of the immunotherapy agent atezolizumab and chemotherapy, according to an institutional study conducted within the Mayo Clinic.

Treatment with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia led to a significant improvement in progression-free survival, meeting the primary end point of the phase 3 SEQUOIA clinical trial.

The FDA has granted an orphan drug designation to TST001, an anti-Claudin18/2 monoclonal antibody, for the treatment of gastric cancer or gastroesophageal junction.

In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the DUO-E trial, its design, end points, and the need for novel endometrial cancer therapies. 

Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.

A warning from the FDA highlights that an increased rate of death has been observed in patients with multiple myeloma who are undergoing treatment with the FDA-approved agent melphalan flufenamide in combination with dexamethasone in the phase 2 OCEAN clinical trial.

Selinexor has been administered in combination with ruxolitinib to the first patient with treatment-naïve myelofibrosis as part of a phase 1/2 clinical trial.

Camidanlumab tesirine is a potential treatment option for relapsed or refractory lymphoma with a tolerable safety profile, particularly in patients with classical Hodgkin lymphoma.

Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.

In an interview with Targeted Oncology, Bobbie J. Rimel, MD, discussed the phase 2 NRG-GY012 results and the next step for cediranib plus olaparib as treatment of recurrent or metastatic endometrial cancer.

Wearable medical devices, whether they be smart watches or wearable at-home infusion devices or pumps, are playing a more prominent role in cancer care.

Between 2014 and 2018, there was an overall decline in cancer deaths in men, women, and children of all racial and ethnic groups in the United States.

The first patient with an advanced solid tumor has been dosed with the first-in-class anti-PVRIG antibody, COM701, in combination with nivolumab and the anti-TIGIT antibody, BMS-986207, in a phase 1/2 clinical trial.

In an interview with Targeted Oncology, Guiseppe Curigliano, MD, an associate professor of Medical Oncology at the University of Milano and the head of the Division of Early Drug Development at the European Institute of Oncology, discussed the HER2Climb study and the impact of tucatinib in HER2-positive breast cancer care.

The treatment plan for a woman with multiple myeloma, including which imaging to order, choice of second-line therapy, managing comorbidities, and backbone therapy choice, was discussed during a recent Cased-Base Roundtable event led by Clifton C. Mo, MD.

In an interview with Targeted Oncology, Ainhoa Madariaga, MD, explained the similarities between the primary and exploratory analyses of adavosertib and gemcitabine in patients with ovarian cancer as it relates to toxicity.

DAY101, an investigational, oral, brain-penetrant, and highly selective type II pan-RAF kinase inhibitor for the treatment of rare, pediatric low-grade glioma, was granted a rare pediatric disease designation by the FDA.

Asparaginase has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for the treatment of adult and pediatric patients with acute lymphoblastic leukemia.

In an interview with Targeted Oncology, Melissa M. Hardesty, MD, explained the state of gynecologic oncology treatment for rural patients in Alaska and how research is finding answers for improving clinical outcomes.

Cutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.

The FDA has granted approval to pembrolizumab for the treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

Samantha E. Greenberg, MS, MPH, CGC, discusses if the changes to the National Comprehensive Cancer Network’s Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.

Treatment with mogamulizumab-kpkc in adult patients with cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome, demonstrated better outcomes in those who had higher levels of blood involvement at baseline assessment, according to results of a post-hoc analysis for the MAVORIC trial.

Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.

The FDA has granted an orphan drug designation to the anticancer drug paclitaxel-hyaluronic acid for the treatment of malignant mesothelioma.